Inventor · disambiguated record
Chen Dong
Also filed as: DONG CHEN · DONG CHEN-YUAN
10 granted patents·15 pending applications·194 citations·filing 1996–2024
86Inventor score
Files withSUZHOU KANOVA BIOPHARMACEUTICAL CO LTD6OLARIS INC4UNIV NAT TAIWAN4UNIV WASHINGTON3SHANGHAI HENLIUS BIOTECH INC2
Top patents by PatentIndex Score
25 records- 0190US5814820APump probe cross correlation fluorescence frequency domain microscope and microscopyUNIV ILLINOIS·Filed 1996·Granted Sep 29, 1998·115 cites·18 claims
- 0286US10858427B2Monoclonal antibody against both IL-17A and IL-17F and use of the sameSUZHOU KANOVA BIOPHARMACEUTICAL CO LTD·Filed 2017·Granted Dec 8, 2020·4 cites·15 claims
- 0380US6255642B1Standing wave total internal reflection imagingMASSACHUSETTS INST TECHNOLOGY·Filed 1999·Granted Jul 3, 2001·63 cites·21 claims
- 0476US11485782B2Anti-claudin 18.2 antibodiesBEIJING XUANYI PHARMASCIENCES CO LTD·Filed 2019·Granted Nov 1, 2022·2 cites·16 claims
- 0570US6768122B2Multiphoton excitation microscope for biochip fluorescence assayUNIV NAT TAIWAN·Filed 2002·Granted Jul 27, 2004·10 cites·16 claims
- 0666US2024383995A1Anti-ox40 antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2024·Application pending·0 cites
- 0766US2024383996A1Anti-ox40 antibodies, multispecific antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2024·Application pending·0 cites
- 0861US2023340440A1Genetic manipulation method in bacteriaUNIV WASHINGTON·Filed 2023·Application pending·0 cites
- 0959US2023087439A1Nmr-Metabolite-Signature For Identifying Cancer Patients Resistant To Cdk4/6 Inhibitors, Endocrine Therapy and Anti-HER2 TherapyOLARIS INC·Filed 2022·Application pending·0 cites
- 1055US12378299B2CD80 variant proteins and uses thereofXUANZHU BIOPHARMACEUTICAL CO LTD·Filed 2020·Granted Aug 5, 2025·0 cites·10 claims
- 1155US2008008706A1B7S1: an immune modulatorUNIV WASHINGTON·Filed 2007·Application pending·0 cites
- 1255US2024239892A1Anti-pd-1 polypeptides and their useSUZHOU KANOVA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1353US2024239887A1Anti-tigit antibodies and their useSUZHOU KANOVA BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1451US2020116657A1Nmr-metabolite-signature for identifying cancer patients resistant to cdk4/6 inhibitors, endocrine therapy and anti-her2 therapyOLARIS INC·Filed 2019·Application pending·0 cites
- 1551US2022326224A1Spectographic Metabolite-Signature for Identifying a Subject's Susceptibility to DrugsOLARIS INC·Filed 2022·Application pending·0 cites
- 1650US2005163772A1B7S1: an immune modulatorUNIV WASHINGTON·Filed 2004·Application pending·0 cites
- 1748US11366102B2Spectographic metabolite-signature for identifying a subject's susceptibility to drugsOLARIS INC·Filed 2019·Granted Jun 21, 2022·0 cites·19 claims
- 1848US2010247547A1Modulation of the th-17 cell mediated immune responsesDONG CHEN·Filed 2008·Application pending·0 cites
- 1946US12258392B2Anti-IL-25 antibodies and use thereofSUZHOU KANOVA BIOPHARMACEUTICAL CO LTD·Filed 2018·Granted Mar 25, 2025·0 cites·13 claims
- 2045US2024068043A1Method and kit for monitoring non-small cell lung cancerUNIV NAT TAIWAN·Filed 2022·Application pending·0 cites
- 2142US12358985B2Anti-B7S1 polypeptides and their useSUZHOU KANOVA BIOPHARMACEUTICAL CO LTD·Filed 2020·Granted Jul 15, 2025·0 cites·17 claims
- 2242US12187800B2Anti-B7-H3 antibodySUZHOU KANOVA BIOPHARMACEUTICAL CO LTD·Filed 2018·Granted Jan 7, 2025·0 cites·17 claims
- 2341US2009185980A1In vivo drug screening systemUNIV NAT TAIWAN·Filed 2008·Application pending·0 cites
- 2437US2012035444A1Intravital sample device for in vivo drug screeningDONG CHEN-YUAN·Filed 2011·Application pending·0 cites
- 2531US2011178410A1Method of Quantitative Analysis Utilizing Multiphoton MicroscopyUNIV NAT TAIWAN·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Chen Dong files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →